Last reviewed · How we verify
NCT06234033
Neural Mechanisms of Sensory Processing Anomalies
trial testing Discrimination Acuity test in Attention Deficit Hyperactivity Disorder in 75 participants. Status unknown.
31 October 2025
Quick facts
| Lead sponsor | Aalborg University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 1 November 2023 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Discrimination Acuity test
- Transiently Evoked Otoacoustic Emission
- Questionnaires
- Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)
- Clinical tests of ASD
- Electroencephalography (EEG) with auditory or vibrotactile stimuli
- Clinical tests of ADHD
Conditions studied
- Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
- Sensory Processing Disorder — all drugs for Sensory Processing Disorder →
Sponsor
Aalborg University
Who can join
Adults 8 to 15, any sex, with Attention Deficit Hyperactivity Disorder or Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess sensory processing anomalies in neurotypical children, children with autism spectrum disorder, and attention-deficit hyperactivity disorder, particularly within the vibrotactile and auditory sensory modalities.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06234033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention Deficit Hyperactivity Disorder
Currently open trials in the same condition.
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
- NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
- NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
- NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting
Other Aalborg University trials
Trials by the same sponsor.
- NCT07580989 — Network Effects of Left M1 rTMS: A TMS-EEG Study · NA · recruiting
- NCT07395882 — A New Model to Induce Itch and Inflammation · NA · not yet recruiting
- NCT07395869 — Off-set Analgesia Induced by Cold Temperature · NA · not yet recruiting
- NCT07266103 — Mechanistic Study of Personalized rTMS in Chronic Pain · NA · not yet recruiting
- NCT07373392 — Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals Wi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06234033 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aalborg University
- Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06234033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing